Tag
A UK Biobank study reveals that optimal sleep (6-8 hours) improves executive function and reduces dementia risk in focal epilepsy patients, with effects surpassing those in stroke patients. Nonoptimal sleep exacerbates cognitive deficits up
A large multicenter real-world study indicates that cenobamate provides superior effectiveness and seizure freedom rates compared to brivaracetam, lacosamide, and perampanel in adults with drug-resistant focal epilepsy, despite a higher inc
A multicentre prospective nested case‑control analysis (REPO2MSE) identifies extratemporal seizure onset, BMI ≥30, male sex, and predominantly nocturnal seizures as independent SUDEP risk factors in drug‑resistant focal epilepsy; peri‑ictal
A 12-month US prospective observational study found brivaracetam retention at 12 months of 57% (intent-to-treat) and 72% among those with known treatment status, early improvement in seizure-related disability and PROMIS domains, and a safe
New data reveal many patients with focal epilepsy experience seizures beyond the first treatment year, with nearly a quarter developing resistance to antiseizure medications, underscoring the need for optimized treatment strategies.
